 The FDA has approved Mirum Pharmaceuticals Inc NASDAQ: MIRM Livmarli maralixibat oral solution for cholestatic pruritus in patients with Alagille syndrome ALGS one year of age and older. Livmarli, a minimally absorbed ileal bile acid transporter IBAT inhibitor, is the first and only FDA-approved medication in this rare liver disease. 